Danaher Co. (NYSE:DHR) Shares Sold by Veracity Capital LLC

Veracity Capital LLC lowered its stake in Danaher Co. (NYSE:DHR) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,386 shares of the conglomerate’s stock after selling 51 shares during the quarter. Veracity Capital LLC’s holdings in Danaher were worth $318,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of DHR. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher during the 3rd quarter valued at $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter worth $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

Danaher stock opened at $245.95 on Friday. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The company’s fifty day simple moving average is $235.02 and its 200-day simple moving average is $253.41.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

A number of research analysts recently issued reports on DHR shares. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. Raymond James reduced their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a report on Tuesday. Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Barclays decreased their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.